NEJM 新英格兰医学杂志· Cary O. HardingOregon Health and Science University, PortlandNicola LongoUniversity of California, Los Angeles, Los AngelesMarkey McNuttUniversity of Texas Southwestern Medical Center, DallasRani H. SinghEmory University, AtlantaAndreu ViaderGeorge VratsanosHaoling H. WengElaina JureckiFernanda Leal-PardinasJnana Therapeutics, BostonWei LiOtsuka Pharmaceutical Development and Commercialization, Rockville, MDGuissou DabiriJohn P. ThroupJnana Therapeutics, BostonAnia C. Muntaufor the JNT517-101 Trial Investigators Group*University Medical Center Hamburg–Eppendorf, Hamburg, Germany·· 23 天前AI 评分48
JNT517-101 试验:SLC6A19 抑制剂 repinatrabit 对苯丙酮尿症苯丙氨酸水平的影响
SLC6A19 Inhibitor Repinatrabit and Phenylalanine Levels in Phenylketonuria
AI 导读
NEJM 以研究来信形式发表 JNT517-101 试验结果,考察 SLC6A19 抑制剂 repinatrabit 对苯丙酮尿症患者苯丙氨酸水平的影响。文章由 Jnana Therapeutics、Otsuka 及多家大学医学中心的研究者共同署名,刊于第 395 卷第 17 期,页码 1760-1763。
来源:NEJM 新英格兰医学杂志 · nejm.org